The Impact of Nebivolol Versus Metoprolol on Quality of Life

NCT01441570 | Terminated Results

• 1 other identifier: 2011P001638
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 2

Brief Summary

In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population. That is, patients treated with nebivolol reported less side effects compared to those treated with metoprolol. Also, more nebivolol treated patients reached normalization of blood pressure. Although there is no data, it is believed that the impact would be similar in renal transplant recipients. The primary goal of this study is to determine if nebivolol will improve the quality of life measurements of kidney transplant recipients as compared to those treated with metoprolol succinate. This will be measured by comparing the scores of four quality of life questionnaires taken before and after 12 weeks of treatment with study drug. Other aims of this study are to determine if the use of nebivolol is cost-effective in the renal transplant recipient; determine if there is a change in urine protein excretion and renal function with the use of nebivolol; and determine the number of patients that maintain or achieve a target blood pressure of ≤ 120/80 mmHg.

Conditions

Transplant; Failure, Kidney; Hypertension

Keywords

kidney; transplant; hypertension; nebivolol; metoprolol; bystolic; toprol

Outcome Measures

Primary Outcomes (1)

• Quality of Life

  Primary outcome measure will be the change from the Screening/Enrollment Visit to the End of the Study/Early Termination visit in scores of four quality of life questionnaires. The four quality of life questionnaires that were used included the following: 1. Short Form (SF)-36v2 Health Survey (Score Range = 0-100; the lower the score the more disability) 2. Sexual Dysfunction Tool for Men = International Index of Erectile Function (IIEF) Questionnaire (Score Range = 5-25; a score of 22-25 = No erectile dysfunction; 17-21 = Mild erectile dysfunction; 12-16 = Mild to moderate erectile dysfunction; 8-11 = Moderate erectile dysfunction; 5-7 = Severe erectile dysfunction) 3. Sexual Dysfunction Tool for Women = Changes in Sexual Functioning Questionnaire (CSFQ-14-F; Score Range = 14-70; a score at or below 42 is indicative of sexual dysfunction) 4. Multidimensional Assessment of Fatigue (MAF) Scale (Score Range = 1-50; the higher the score the more fatigue)

  12 weeks; Baseline scores were measured at the Initial Screening/Enrollment Visit (Visit 1 - beginning of week 1); Follow-Up scores were measured at the End of the Study (Visit 2 - End of week 12)

Secondary Outcomes (1)

• Blood Pressure

  12 weeks

Study Arms (2)

Nebivolol

ACTIVE COMPARATOR

Drug: Nebivolol

Metoprolol Succinate

ACTIVE COMPARATOR

Drug: Metoprolol succinate

Interventions

Nebivolol DRUG

Subject will take nebivolol daily for 12 weeks.

Also known as: Bystolic

Nebivolol

Metoprolol succinate DRUG

Subject will take metoprolol succinate daily for 12 weeks.

Also known as: Toprol XL

Metoprolol Succinate

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult renal transplant recipients, men and women between 18 and 75 years of age, inclusive.
• Patients must be \> 3 months post-transplant.
• Patients must have stable renal function (stable renal function will be defined as those patients without infection or hospitalization \[for any reason\] over the past 30 days, and patients with \< 20% change in their serum creatinine over the past 30 days.
• Patients receiving corticosteroids must be receiving a daily dose of \< 7.5 mg of prednisone (or therapeutic equivalents based on glucocorticoid equivalency scale).
• All eligible patients must be receiving antihypertensive medication management which must include metoprolol tartrate or metoprolol succinate.
• Patients may be on more than one medication to control their hypertension. Use of any other FDA-approved antihypertensive agent is permitted.
• Patients who are able to comprehend and satisfactorily comply with protocol requirements.
• Patients who signed the written informed consent given prior to entering any study procedure.

You may not qualify if:

• Patients with Stage II/uncontrolled hypertension (\>159/99 mmHg).
• Patients with an easily identifiable etiology for fatigue (i.e. anemia, iron-deficiency, poor sleep patterns, etc.).
• Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial (i.e. arrhythmia).
• Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
• Patients who are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.
• Patients with any contraindications to beta blocker therapy as listed in the package labeling for both metoprolol succinate and nebivolol.

Sponsors & Collaborators

• Brigham and Women's Hospital: lead
• Forest Laboratories: collaborator
• Lahey Clinic: collaborator

Study Sites (2)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Lahey Clinic

Burlington, Massachusetts, 01805, United States

Location

MeSH Terms

Conditions

Hypertension

Interventions

Nebivolol; Metoprolol

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Phenoxypropanolamines; Propanolamines; Propanols

Results Point of Contact

• Title: Dr. Steven Gabardi
• Organization: Brigham and Women's Hospital

sgabardi@partners.org

617-732-7658

Study Officials

• Steven Gabardi, PharmD, FCCP, BCPS

  Transplant Surgery

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Abdominal Organ Transplant Specialist

Study Record Dates

• First Submitted: September 26, 2011
• First Posted: September 27, 2011
• Study Start: February 1, 2012
• Primary Completion: July 1, 2013
• Study Completion: July 1, 2013
• Last Updated: April 20, 2017
• Results First Posted: April 20, 2017

Record last verified: 2017-03

Locations

US (2)